文献速递冠心病

EXCEL试验:左主干冠心病血运重建患者的BNP评估

B-Type Natriuretic Peptide Assessment in Patients Undergoing Revascularization for Left Main Coronary Artery Disease: Analysis From the EXCEL Trial.
PubMed 文献 · Circulation · 2018-01-01

EXCEL试验随机分配左主干冠心病且SYNTAX评分低中危患者接受PCI或CABG,评估基线BNP升高(≥100 pg/mL)与3年不良结局的关系。基线BNP升高者占39.5%,其3年主要复合终点和死亡率显著更高,且BNP状态与血运重建方式存在显著交互作用,提示BNP可能影响PCI与CABG的相对疗效。

要点

  • 左主干冠心病患者基线BNP升高者占39.5%,与3年主要复合终点和死亡率独立相关。
  • BNP升高与心梗、卒中、缺血驱动血运重建、支架血栓、桥血管闭塞或大出血风险无显著差异。
  • BNP状态与PCI versus CABG存在显著交互作用,提示BNP可能影响血运重建方式选择。

核心结论

  • 基线BNP升高与左主干冠心病血运重建患者长期死亡率独立相关,但与非致命性缺血或出血事件无关。
  • PCI versus CABG的相对长期结局可能受基线BNP水平影响。

研究设计与样本

  • EXCEL试验随机对照研究,纳入左主干冠心病且SYNTAX评分低或中危患者,随机接受依维莫司洗脱支架PCI或CABG。
  • 基线BNP升高定义为≥100 pg/mL,共1037例患者中410例(39.5%)升高。
  • 主要终点为全因死亡、心肌梗死或卒中的复合终点,采用多变量Cox回归分析3年风险。

主要发现

  • BNP升高者3年主要复合终点发生率18.6% versus 11.7%,调整后HR 1.62(95%CI 1.16-2.28,P=0.005)。
  • BNP升高者3年死亡率11.5% versus 3.9%,调整后HR 2.49(95%CI 1.48-4.19,P=0.0006),其中心血管和非心血管原因均升高。
  • BNP升高与正常组在心肌梗死、卒中、缺血驱动血运重建、支架血栓、桥血管闭塞或大出血风险上无显著差异。
  • BNP升高与治疗方式交互作用P=0.03:BNP升高者PCI versus CABG调整后HR 1.54(95%CI 0.96-2.47),BNP正常者HR 0.74(95%CI 0.46-1.20)。
  • 以log(BNP)为连续变量建模时交互作用更强(P=0.002)。

关键数值与推荐

  • BNP升高定义为基线BNP≥100 pg/mL。
  • 主要终点为3年全因死亡、心肌梗死或卒中的复合终点。
  • BNP升高者主要复合终点调整后HR 1.62(95%CI 1.16-2.28,P=0.005),死亡率调整后HR 2.49(95%CI 1.48-4.19,P=0.0006)。

临床怎么用

  • 对左主干冠心病血运重建患者,基线BNP升高提示长期死亡风险增加,应加强风险分层和随访。
  • BNP状态可能为PCI与CABG的选择提供参考,但需进一步研究验证。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elevated B-type natriuretic peptide (BNP) is reflective of impaired cardiac function and is associated with worse prognosis among patients with coronary artery disease (CAD). We sought to assess the association between baseline BNP, adverse outcomes, and the relative efficacy of percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) in patients with left main CAD. METHODS: The EXCEL trial (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) randomized patients with left main CAD and low or intermediate SYNTAX scores (Synergy Between PCI With TAXUS and Cardiac Surgery) to PCI with everolimus-eluting stents versus CABG. The primary end point was the composite of all-cause death, myocardial infarction, or stroke. We used multivariable Cox proportional hazards regression to assess the associations between normal versus elevated BNP (≥100 pg/mL), randomized treatment, and the 3-year risk of adverse events. RESULTS: BNP at baseline was elevated in 410 of 1037 (39.5%) patients enrolled in EXCEL. Patients with elevated BNP levels were older and more frequently had additional cardiovascular risk factors and lower left ventricular ejection fraction than those with normal BNP, but had similar SYNTAX scores. Patients with elevated BNP had significantly higher 3-year rates of the primary end point (18.6% versus 11.7%; adjusted hazard ratio [HR], 1.62; 95% confidence interval [CI], 1.16-2.28; P=0.005) and higher mortality (11.5% versus 3.9%; adjusted HR, 2.49; 95% CI, 1.48-4.19; P=0.0006), both from cardiovascular and noncardiovascular causes. In contrast, there were no significant differences in the risks of myocardial infarction, stroke, ischemia-driven revascularization, stent thrombosis, graft occlusion, or major bleeding. A significant interaction ( Pinteraction=0.03) was present between elevated versus normal BNP and treatment with PCI versus CABG for the adjusted risk of the primary composite end point at 3 years among patients with elevated BNP (adjusted HR for PCI versus CABG, 1.54; 95% CI, 0.96-2.47) versus normal BNP (adjusted HR, 0.74; 95% CI, 0.46-1.20). This interaction was stronger when log(BNP) was modeled as a continuous variable ( Pinteraction=0.002). CONCLUSIONS: In the EXCEL trial, elevated baseline BNP levels in patients with left main CAD undergoing revascularization were independently associated with long-term mortality but not nonfatal adverse ischemic or bleeding events. The relative long-term outcomes after PCI versus CABG for revascularization of left main CAD may be conditioned by the baseline BNP level. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01205776.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Redfors B, Chen S, Crowley A, et al. B-Type Natriuretic Peptide Assessment in Patients Undergoing Revascularization for Left Main Coronary Artery Disease: Analysis From the EXCEL Trial. Circulation. 2018. PMID: 29666071. doi:10.1161/CIRCULATIONAHA.118.033631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。